EECP® Reported to Have Benefit for Patients with Type II Diabetes

PLAINVIEW, N.Y. – May 31, 2016 – This month a randomized clinical study entitled “Enhanced External Counterulsation (EECP®) Decreases Advanced Glycation End-Products and Proinflamatory Cytokines in Patients with Non-Insulin Dependent Type II Diabetes” was published in Acta Diabetologica, a scientific peer-reviewed journal that publishes reports of experimental and clinical research on diabetes and related metabolic diseases. The study, authored by PD Sardina, JS Martin,, JC Avery and RW Braith from the University of Florida, Gainesville, Auburn University and Edward Via College of Osteopathic Medicine in Alabama, demonstrated that EECP® therapy significantly decreased fasting plasma glucose (FPG), significantly reduced A1c and cytokines (inflammatory markers), while significantly increasing nitric oxide.

The authors concluded that EECP® improves glycemic control in patients with Type II Diabetes and these benefits persist for up to 3 months following EECP® therapy.

In 2012, the American Diabetes Association reported that 1.4 million Americans are diagnosed with diabetes every year. Of the 29.1 million Americans with diabetes, 21.0 million were diagnosed, and 8.1 million remain undiagnosed. The percentage of seniors over the age of 65 remains high at 25.9%. Diabetes remains the 7th leading cause of death in the U.S.

©2017 Vaso Corporation